Follow this link:
Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel...

Link:
CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023

Read this article:
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Read more:
Intelligent Bio Solutions Inc. Announces Closing of Private Placement Offering

View original post here:
Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe...

Go here to read the rest:
Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches of Financing Facility

Excerpt from:
Basilea announces regulatory approval of antifungal Cresemba® (isavuconazole) in Japan

Read more:
Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate

Read more from the original source:
Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Advance the Development of Equine...

Read more:
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial  

See the article here:
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

See the article here:
Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Read the rest here:
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101

Go here to see the original:
Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH

See the rest here:
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO

Excerpt from:
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer

View original post here:
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan

See the original post:
FDA approves Roche’s Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphoma

Originally posted here:
Galapagos receives transparency notification from FMR LLC

Read this article:
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or...